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Abstract
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Background and Objective—Boronated porphyrins have emerged as promising dual
sensitizers for use in both photo-dynamic therapy (PDT) and boron neutron capture therapy
(BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and easy
synthesis with high boron content. Octa-anionic 5,10,15,20-tetra[3,5-(nidocarboranylmethyl)phenyl] porphyrin (H2OCP) is a boronated porphyrin having eight boron
clusters linked to the porphyrin ring. To evaluate H2OCP’s applicability to both PDT and BNCT,
we performed an in vitro and ex vivo study using F98 rat glioma cells.
Materials and Methods—We examined the time-dependent cellular uptake of H2OCP by
measuring the boron concentration over time, and compared the cellular uptake/clearance of boron
after exposure to H2OCP in conjunction with boronophenylalanine (BPA) and sodium borocaptate
(BSH), both of which are currently used in clinical BNCT studies. We evaluated the cytotoxicity
of H2OCP-mediated PDT using a colony-forming assay and assessed the tumor-igenicity of the
implantation of pre-treated cells using Kaplan–Meier survival curves. Fluorescence microscopy
was also performed to evaluate the cellular uptake of H2OCP.
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Results—H2OCP accumulated within cells to a greater extent than BPA/BSH, and H2OCP was
retained inside the cells to approximately the same extent as BSH. The cell-surviving fraction
following laser irradiation (8 J/cm2, 18 hours after exposure to 10 μg B/ml H2OCP) was <0.05.
The median survival times of the pre-treated cell-implanted rats were longer than those of the
untreated group (P < 0.05). The fluorescence of H2OCP was clearly demonstrated within the
tumor cells by fluorescence microscopy.
Conclusions—H2OCP has been proven to be a promising photosensitizer for PDT. H2OCP has
also been proposed as a potentially effective replacement of BPA or BSH, or as a replacement of
both BPA/BSH. Our study provides more evidence that H2OCP could be an effective novel dual
sensitizing agent for use in both PDT and BNCT.
Keywords
boron neutron capture therapy; boronated porphyrin; F98 rat glioma cells; H2OCP; photodynamic
diagnosis; photodynamic therapy
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INTRODUCTION
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The prognosis of patients with malignant glioma, especially glioblastoma (GB), is poor. The
median survival of GB patients is <2 years after the initial diagnosis [1], with most
recurrence occurring at the site of the original tumor. Therefore, more aggressive local
therapies are necessary to eradicate unresectable tumor cells that invade adjacent normal
brain tissue. Two adjuvant therapies with the potential to destroy these cells are
photodynamic therapy (PDT) [2–4] and boron neutron capture therapy (BNCT) [5–8]. Both
are bimodal therapies, the individual components of which are non-toxic in isolation but
tumoricidal in combination. Boronated porphyrins have emerged as promising dual
sensitizers for both PDT and BNCT by virtue of the following characteristics: tumor affinity
by the porphyrin ring; ease of synthesis with a high boron content; low cytotoxicity in dark
conditions; and desirable photophysical properties, including strong light absorption in the
visible and near infrared regions, the ability to generate singlet oxygen upon light activation,
and fluorescence properties [9,10]. Several boronated porphyrins have been synthesized and
evaluated in cellular and animal studies [9,10]. Among these, boronated porphyrins BOPP
[11,12] and CuTCPH [13], each containing four boron clusters, have been extensively
investigated. This type of boronated porphyrin was found to selectively deliver therapeutic
concentrations of boron into tumor cells with low cytotoxicity in dark conditions and with
long retention times within tumors. Boronated porphyrins having high boron content (up to
16 boron clusters) have been reported, [9,14] and it has been postulated that this type of
compound could potentially deliver higher amounts of boron to tumors at the same dose. In
particular, the synthesis and cellular evaluation of the octa-anionic 5,10,15,20–tetra[3,5–
(nido–carboranylmethyl)phenyl] porphyrin (H2OCP), containing eight boron clusters (38%
boron by weight), have been reported previously by the authors[15]. In that study, H2OCP
was shown to deliver high amounts of boron to human glioma T98G cells with low
cytotoxicity in dark conditions. In this study, we evaluated the potential of H2OCP as a dual
sensitizer for both PDT and BNCT using F98 rat glioma cells. Although several boronated
porphyrins have been proposed as boron delivery agents for BNCT, only a few have been
investigated as dual sensitizers for both PDT and BNCT of tumors [9,16].
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MATERIALS AND METHODS
Boron Delivery Agents
The H2OCP was prepared as previously described [15]. Boronophenylalanine (BPA) (Lisomer) was kindly supplied by the Stella Chemifa Corporation (Osaka, Japan) and was
prepared as a fructose complex [17]. Sodium borocaptate (BSH) was purchased from
Katchem Ltd. (Katchem, Prague, Czech Republic) and dissolved in sterile saline.
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Cell Culture
F98 rat glioma cells produce infiltrating tumors in the brains of Fischer rats[18]. The tumors
have been shown to be refractory to a number of treatment modalities, including radiation
therapy [19]. Based on their in vivo histology, the F98 rat glioma cells have been
characterized as anaplastic or undifferentiated glioma [20]. In the present study, F98 rat
glioma cells were kindly obtained from Dr. Barth (Department of Pathology, the Ohio State
University, Columbus, OH). They were routinely cultivated in our laboratory in Dulbecco’s
Modified Eagle Medium supplemented with 10% fetal bovine serum and penicillin at 37°C
in an atmosphere of 5% CO2. All the materials for the culture medium were purchased from
Gibco Invitrogen (Grand Island, NY).
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Cellular Uptake/Clearance of Boron
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The F98 rat glioma cells were seeded in 100 mm dishes (BD Falcon™, Franklin Lakes, NJ),
and the culture medium without H2OCP was exchanged for the H2OCP-containing culture
medium just before confluence. In all cellular studies, three 100 mm dishes for each cellular
study were used. H2OCP was dissolved in DMSO prior to dilution into the culture medium;
the final DMSO concentrations never exceeded 1%. After the completion of exposure, the
H2OCP-containing culture medium was removed and the cells were washed twice with 4°C
phosphate-buffered saline (PBS). Finally, the cells were retrieved using trypsin and fed 60%
nitric acid in the cellular solution to extract intracellular boron. In order to evaluate the timedependent boron uptake, the cells were exposed to 20 μg B/ml of H2OCP for 6, 12, or 18
hours. Cellular uptake/clearance experiments were conducted using culture media
containing 20 μg B/ml boron from either the H2OCP, BPA, or BSH stock solutions and were
exposed to the cells for a 12-hour period, followed by clearance times of 0, 2, and 6 hours.
The boron concentrations were analyzed by inductively coupled plasma atomic emission
spectrometry (ICP-AES) using an iCAP6000 emission spectrometer (Hitachi HighTechnologies, Tokyo, Japan). PBS and trypsin were purchased from Gibco Invitrogen, and
the 60% nitric acid was purchased from Wako Pure Chemical Industries (Osaka, Japan).
Colony-Forming Assay
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F98 rat glioma cells were incubated in culture media with two different doses of H2OCP (5
and 10 μg B/ml) and without H2OCP (control) for 18 hours in 150 cm2 flasks (TPP®;
Zollstrasse, Trasadingen, Switzerland). Following incubation, the cells were retrieved from
the flasks, seeded onto 60 mm dishes (BD Falcon™) with 104 cells each and irradiated with
visible light of 405 nm from a diode laser (Ball Semiconductor, Frisco, TX). The cells were
evenly irradiated at powers of 0 (control), 2, 4, and 8 J/cm2. Following laser irradiation, the
cells were seeded onto dishes; each with the same predetermined number of cells,
iteratively. After 7 days, all of the colonies (>50 cells) were counted and assessed by
calculating the cell-surviving fraction.
Tumorigenesis of In Vitro Pre-Treated Tumor Cells
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In the treated group, F98 cells were exposed to 20 μg B/ml H2OCP for 12 hours at 37°C
prior to laser irradiation (4 J/cm2), after which the tumor cells were implanted into 10 male
Fischer rats. As a control study, untreated F98 cells were prepared and implanted in five
male rats. Dead cells were stained with trypan blue just before implantation, counted under
microscope, and expressed as a percentage of total cells perfield-of-view segment. Viable
cells were counted and were implanted into the rat brains. All male Fischer rats (200–250
mg) were anesthetized with an intraperitoneal injection of Nembutal (50 mg/kg) and placed
in a stereotactic frame (Model 900, David Kopf Instruments, Tujunga, CA). A mid-line
scalp incision was made and the bregma was identified. A 1 mm burr hole was made in the
right frontal region of the skull and a 22-gauge needle attached to a 25 μl syringe was
inserted into the caudate nucleus using the same stereo-tactic coordinates, with the needle tip
inserted 5 mm into the dura. An injection of 105 cells in 10 μl of serum free medium was
administered at a rate of 1 μl/minute. After the infusion, the needle was left in place for 3
minutes and the burr hole was then covered with bone wax. After implantation surgery, the
body weight and neurological function of the rats were monitored daily. One day before
death became imminent (defined by significant weight loss and a lack of activity or severe
neurological deficits), the rats were euthanized and Kaplan–Meier survival curves were
plotted and analyzed.
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Cytotoxicity of H2OCP in Dark Conditions
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We examined the cytotoxicity of H2OCP in the dark with a viablecell-counting method and
a colony-forming assay. F98 rat glioma cells were seeded in 100 mm dishes and were
incubated in culture media containing two different concentrations of H2OCP (0, 20 μg B/
ml) for cell counting. After exposure to H2OCP for 24 hours, the cells were counted using
the trypan blue dye exclusion method. This assay was performed in triplicate. The
cytotoxicity in the cell count was assessed by the percentage of viable of cells. For the
colony-forming assay, F98 rat glioma cells were seeded in 100 mm dishes and were
incubated in culture media containing five different concentrations of H2OCP(0,5,10,20,40
μg B/ml). After exposure to H2OCP for 24 hours, the cells were retrieved from the dishes
and were seeded onto 100 mm dishes, each with the same predetermined number of cells.
This assay was also performed in triplicate. After 7 days, all of the colonies (>50 cells) were
counted and assessed by calculation for the cell-surviving fraction.
Fluorescence Microscopy
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F98 rat glioma cells were seeded in a two-well chamber mounted on glass slides with a
cover (Nalge Nunc International, Rochester, NY) and the culture medium without H2OCP
was exchanged for the H2OCP-containing culture medium just before confluence. The cells
were exposed to 20 μg B/ml H2OCP for 24 hours. After exposure, the glass slides were
washed with 4°C PBS and the two-well chamber was removed. The nucleus-specific hoechst
dye (Hoechst 33342, Lonza, Maryland, MD) was added (10 μg/ml) and the glass slides
mounted onto cover glasses using DPX Mountant for histology (44581, Fluka Biochemika,
Darmstadt, Germany). The two-well chamber slides were observed using an inverted
fluorescence microscope system (BZ-8000, Keyence, Tokyo, Japan).

RESULTS
Cellular Uptake/Clearance of Boron
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The measured cellular boron concentrations obtained by in vitro cellular delivery using
H2OCP were 158.2 ± 3.8, 272.2 ± 15.3, and 405.1 ± 22.6 ng B/ml 106 cells after 6, 12, and
18 hours of exposure, respectively. Nearly three times more boron was found within cells
after 18 hours of exposure than after 6 hours of exposure (Fig. 1). The determined cellular
boron concentrations for in vitro cellular uptake/clearance of boron in response to exposure
to H2OCP, BPA, and BSH for 12 hours were 272.2 ± 15.3, 239.7 ± 12.3, and 85.2 ± 2.0 ng
B/ml 106 cells, respectively. In contrast, at 6 hours after exposure the cellular boron
concentrations were 246.7 ± 14.6, 84.9 ± 0.7, and 67.0 ± 4.6 ng B/ml 106 cells, respectively.
At the same boron dose, H2OCP delivered significantly higher amounts of boron to cells
than did BPA or BSH (log-rank test, P < 0.05). Furthermore, while BPA cleared rapidly
from cells, both H2OCP and BSH showed high cellular retention of boron for up to 6 hours
(Fig. 2).
Colony-Forming Assay
The cytotoxicity of H2OCP determined by laser irradiation using a colony-forming assay
showed that the surviving fraction of cells following exposure to H2OCP (10 μg B/ml for 18
hours) and laser irradiation was 0.326 ± 0.031, 0.246 ± 0.037, and 0.045 ± 0.001 using 2, 4,
and 8 J/cm2 light dose, respectively. Under the same conditions, the surviving fractions of
the laser-only control (without H2OCP) were 0.861 ± 0.182, 0.776 ± 0.035, and 0.299 ±
0.023, respectively. The most efficient PDT-induced tumoricidal effect was achieved when
the cells were irradiated with 8 J/cm2, 18 hours after exposure to H2OCP (<0.05) (Fig. 3).

Lasers Surg Med. Author manuscript; available in PMC 2011 September 1.

Hiramatsu et al.

Page 5

Tumorigenesis of In Vitro Pre-Treated Tumor Cells
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The observed tumorigenicity of the implanted pre-treated cells using Kaplan–Meier survival
curves revealed median survival times of 12 and 14 days in the untreated and the treated
groups, respectively, and mean survival times of 11.8 and 14.6 days after implantation,
respectively. In Kaplan–Meier survival curve analysis, these survival times demonstrated a
significant difference (log-rank test, P < 0.05) (Fig. 4).
Cytotoxicity of H2OCP in Dark Conditions
The viable cell-counting method revealed the following results. The percentage of cell
viability with exposure of 20 μg B/ml H2OCP was 98.0 ± 1.4% (mean ± SD), while that of
cell viability without H2OCP was 98.0 ± 0.9%. The colony-forming assay showed the
following: the surviving fractions with each boron concentration (0, 5, 10, 20, 40 μg B/ml
H2OCP) were 1, 0.99 ± 0.04 (mean ± SD), 0.98 ± 0.05, 0.98 ± 0.01, and 0.98 ± 0.03,
respectively. These results showed no significant differences (Welch’s t-test, P > 0.05).
Fluorescence Microscopy
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The fluorescence microscopy showed the intracellular porphyrin fluorescence and images
from the co-localization experiment using the nucleus-specific Hoechst dye. These results
showed that H2OCP was taken up into the cells and also localized in the nuclei (Fig. 5B–D).
Although the cells showed evidence of cytotoxic damage, the cytotoxicity of H2OCP in dark
conditions was not found at twice the concentration of H2OCP used in this fluorescence
microscopy experiment. (Fig. 5A).

DISCUSSION
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BNCT is a targeted chemo-radiation therapy that significantly increases the therapeutic ratio
relative to conventional radiotherapeutic modalities. In BNCT, a 10B-labeled compound
delivers therapeutic concentrations of 10B (~30 μg 10B/g tumor) to the target tumor, with
high tumor-to-blood and tumor-to-normal-tissue ratios and low cytotoxicity [5,6].
Subsequently the tumor is irradiated with epithermal neutrons that become thermalized at a
certain depth within the tissues. The short range (<10 μm) of the α and 7Li high linear
energy transfer (high-LET) particles released from the 10B(n, α) 7Li neutron capture reaction
makes the tumor microdistribution of 10B critically important in BNCT [21]. Since the highLET particles are highly cytotoxic, their killing effect depends on the site of generation.
These characteristics contribute to the tumor selectivity and strong tumoricidal activity of
BNCT, with negligible damage to normal tissue. Therefore, if sufficient quantities of boron
can be selectively delivered to tumor tissues, BNCT could be an ideal tumor-selective
particle beam irradiation local therapy for malignant gliomas. Clinically, BPA and BSH are
currently available for BNCT as boron delivery agents. BPA is a boronated derivative of an
essential amino acid (L-phenylalanine) that is actively taken up by tumor cells, presumably
via the amino acid transport mechanism [22]. BSH, on the other hand, is believed to
preferentially accumulate within tumor tissue via a partially destroyed or leaky blood brain
barrier, and is thought to be retained longer than BPA due to its higher hydrophobic
character [23]. We have used both of these boron delivery agents in combination in clinical
BNCT studies, and have previously been reported on the survival benefit from BNCT for
newly diagnosed GB patients [7] as well as for recurrent malignant glioma patients [8].
However, the present results using BPA and BSH are far from satisfactory, and the use of
more effective boron delivery agents should provide enhanced clinical outcomes for BNCT.
The so-called third-generation of boron delivery agents [6], including boronated porphyrin
derivatives, molecular-targeted agents (e.g., to EGFR), and liposome-linked boron delivery
agents could potentially greatly increase the efficacy of BNCT in the clinical setting. Among
these boron delivery agents, boronated porphyrins are particularly promising because they
Lasers Surg Med. Author manuscript; available in PMC 2011 September 1.
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contain a porphyrin ring with tumor affinity, and they are also excellent photosensitizers for
PDT [9]. In a similar fashion to BNCT, PDT is a localized therapy that relies on the specific
uptake of a photosensitizer in the tumor relative to the surrounding normal tissue, followed
by laser irradiation for activation of the photosensitizer [2,24]. The photoactivation of the
sensitizer causes oxidative damage to a variety of cellular targets via the release of singlet
oxygen and other reactive oxygen species, with subsequent tumor necrosis. To date, the
clinical trials with PDT employed as an adjuvant treatment for human gliomas have used the
poorly defined heterogeneous porphyrin mixture hematoporphyrin derivative (HpD) or its
more enriched commercial preparation, Photofrin [2], which does not contain boron. This
photosensitizer has been shown to localize preferentially in glioma relative to normal brain
tissue. Moreover, reports of PDT as a treatment for animal and human glioma have been
encouraging, and a photosensitizer that is more tumor selective than HpD or Photofrin
would have great clinical benefits.

NIH-PA Author Manuscript

In this study, our results showed the positive efficacy of PDT using H2OCP in a colonyforming assay (Fig. 3) and in tumorigenesis of in vitro pre-treated cells in Fisher rats (Fig.
4). Additionally, H2OCP accumulated within the glioma cells to a significantly higher extent
than BPA or BSH (P < 0.05), and was retained inside the cell to approximately the same
extent as BSH (Fig. 2). Based on these findings, we postulated that H2OCP could be applied
to both PDT and BNCT for treatment of glioma tumors. In the fluorescence microscopy
experiment, although the cells in the bright field image showed evidence of cytotoxic
damage (Fig. 5A), the cytotoxicity of H2OCP in dark conditions was not observed, even at
double the concentration of H2OCP used in the fluorescence microscopy experiment.
Therefore, we considered that the damage to the cells in the bright field image was most
probably due to technical complications related to irradiation with the laser during imaging,
rather than to the cytotoxic effects of H2OCP itself. Furthermore, H2OCP was shown to be
taken up by F98 rat glioma cells (Fig. 5B–D). Therefore, our results suggest that H2OCP can
be used intraoperatively for photodynamic diagnosis (PDD) and fluorescence-guided
resection of brain tumors.
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Pre-operative administration of a boronated porphyrin has a number of advantages in the
clinical setting. As noted previously, boronated porphyrins are useful in PDD and in
fluorescence-guided resection of brain tumors during surgery. Using fluorescence-guided
resection of such tumors during surgery, the resection rate can be augmented, with expected
further improvements in patient prognosis [25]. In addition, boronated porphyrins can be
used with intra-operative PDT and post-operative BNCT. Although the initial results with
commonly used photosensitizers for PDT such as Photofrin (or its unpurified form HpD)
were very encouraging, treatment failures did occur, mainly due to the limited penetration of
light into the brain. In cases with deep lesions, PDT alone may be inadequate to achieve
complete tumor treatment, and it would be preferable in such cases to use BNCT as a
supplementary treatment, with boron-containing porphyrin as a photosensitizer. Fairchild et
al. [26] reported that thermal and epithermal neutrons are transported to a depth of
approximately 10 cm in fact, BNCT has been shown to treat deep lesions. Since boronated
porphyrins can be effective for BNCT as boron delivery agents while retaining their
photosensitizer ability, the limited penetration of light can be overcome using a combination
of BNCT and PDT for the treatment of human gliomas.
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Fig. 1.

Cellular uptake of boron (ng B/ml 106 cells) after 6, 12, and 18 hours of exposure to 20 μg
B/ml H2OCP.
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Fig. 2.
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Comparison of cellular uptake/clearance of boron (ng B/ml 106 cells) after exposure to 20
μg B/ml of either H2OCP, BPA, or BSH under identical conditions. Left and right Y-axes
show the measured value (ng B/ml 106 cells) and percentage of boron concentration,
respectively. The cellular uptake of boron using H2OCP showed values higher than those for
BPA and BSH (P < 0.05), and the cellular retention of boron using H2OCP showed values
similar to those obtained using BSH.
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Fig. 3.

Colony-forming assay using F98 rat glioma cells exposed to 0 (control), 5, and 10 μg B/ml
of H2OCP and irradiated with light doses of 0, 2, 4, and 8 J/cm2, respectively. The cellsurviving fraction following laser irradiation (8 J/cm2, 18 hours after exposure to 10 μg B/ml
H2OCP) was < 0.05.
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Fig. 4.
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Kaplan–Meier survival curves following in vitro pre-treated F98 cells using H2OCPmediated PDT. Rats were implanted i.c. with F98 cells and were either untreated (dotted
line) or treated with PDT (continuous line). Cells were exposed to 20 μg B/ml of H2OCP for
24 hours at 37°C prior to laser irradiation. After laser irradiation (4 J/cm2), the tumor cells
were implanted into the rats. Cell viability was determined by trypan blue exclusion staining
and 105 viable cells were implanted stereotactically into the caudate nucleus. The median
survival times of the untreated control and the treated group were 12 and 14 days, and the
mean survival times were 11.8 and 14.6 days after implantation, respectively (P < 0.05).
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Fig. 5.
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Images obtained using an inverted fluorescence microscope. A: Bright field image.
Although the cells showed evidence of cytotoxic damage, the cytotoxicity of H2OCP in dark
conditions was not found at twice the concentration of H2OCP used in this fluorescence
microscopy experiment. B: Fluorescence of porphyrin H2OCP. C: Nuclear fluorescence by
Hoechst dye (excitation wavelength was 340–380 nm). D: Merged image. (Magnification of
all images: ×600).
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